Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
Part of paid clinical trials in Stanford, California.
- Sponsor
- Stanford University
- Study ID
- NCT00398177
- Status
- Recruiting
Conditions
- Hodgkin's Disease
- Lymphoma, Non-Hodgkin
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The purpose of this study is to characterize the molecular and cell biology of the tumor cells in lymphoma.
Key Dates
- Start date
- Jan 31, 1999
- Status verified
- Dec 2025
- Primary completion
- Jan 31, 2099
- Completion
- Jan 31, 2099
Study Design
- Enrollment
- 9,999 participants (estimated)
Primary Outcome Measure
Collection of tumor tissue to characterize the molecular and cell biology of tumor cells in lymphoma. [ Time Frame: The study will continue indefinitely. ]
Central Contacts
- Alyssa M Kanegai650-736-1596
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University School of Medicine | Stanford | California | 94305 | Ronald Levy (PRINCIPAL_INVESTIGATOR) Shoshana Levy (SUB_INVESTIGATOR) |
Find similar trials in Stanford, CA
By research site
Related Studies
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerPHASE2 · Recruiting · American Society of Clinical Oncology · Birmingham, Alabama
- Long-Term Follow-up StudyEnrolling By Invitation · Caribou Biosciences, Inc. · Birmingham, Alabama
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin LymphomaPHASE1/PHASE2 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.PHASE1 · Recruiting · OncoNano Medicine, Inc. · Los Angeles, California